Understanding Immunotherapy Response in Liver Cancer
Part of Cancer, Digestive system clinical trials.
This study collects tumor samples and medical information from patients with liver cancer to understand why some patients respond better to immunotherapy (immune-boosting drugs) than others. The goal is to improve treatment selection and outcomes for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Confirmed or suspected hepatocellular carcinoma (a type of liver cancer)
- Available tumor tissue from a biopsy or surgery
- Either previously treated with immunotherapy or targeted drugs, or scheduled to receive systemic treatment or local treatment (surgery/ablation)
- Able to provide informed consent for use of tissue samples and medical data
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood and tissue samples from people with liver cancer to find markers that can predict how well treatment works and whether the cancer might come back. It may help doctors personalize treatment and follow-up care.
This study looks at how well immunotherapy combinations work as the first treatment for advanced liver cancer that can't be surgically removed. It will track real-world patients to see how safe and effective these treatments are.
This study looks at whether certain blood markers can predict how well the combination of atezolizumab and bevacizumab works for people with advanced liver cancer. It aims to find out if these markers can help guide treatment decisions.
This study looks at how doctors can use imaging scans to predict how well immunotherapy will work for people with liver cancer that cannot be removed by surgery. Participants must have already received immunotherapy and have had baseline scans.
This study is looking at people with advanced liver cancer (HCC) that cannot be removed by surgery. Researchers want to see if certain markers in your blood or tumor can help predict how well you respond to a combination of chemotherapy delivered directly to the liver and immunotherapy. If you join, you will receive the planned treatment and provide additional blood and tissue samples for analysis.
This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.